Almost $73 m GP generated in 2HFY23 ALONE so expected FY24 GP $150 m double FY22 , therefore the result is 150m -102m = 50M EBITDA . this is going back to 8.85 soon as per analysts recommendation plus the buy back will push the price up further . Further cost reductions of $10 m planned . International revenue growth and launch of nexstellis in australia will further add on to the +ve result .
- Forums
- ASX - By Stock
- 2HFY23 EBITDA up $ 99.9 m from 1FY23
MYX
mayne pharma group limited
Add to My Watchlist
0.20%
!
$5.08

Almost $73 m GP generated in 2HFY23 ALONE so expected FY24 GP...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.08 |
Change
0.010(0.20%) |
Mkt cap ! $412.7M |
Open | High | Low | Value | Volume |
$5.13 | $5.15 | $5.08 | $445.2K | 87.01K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 810 | $5.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.15 | 2033 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 810 | 5.080 |
2 | 3150 | 5.040 |
1 | 600 | 5.030 |
3 | 3000 | 5.000 |
1 | 10000 | 4.980 |
Price($) | Vol. | No. |
---|---|---|
5.150 | 2033 | 2 |
5.180 | 2396 | 2 |
5.190 | 5000 | 1 |
5.200 | 157 | 1 |
5.210 | 5000 | 1 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online